# OnCo record paper-nhs-galleri-performance-nat-med-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nhs-galleri-performance-nat-med-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nhs-galleri-performance-nat-med-2026" ;
  schema:name "Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial"@en ;
  schema:description "In the NHS-Galleri trial about one person in a hundred had a positive blood test in each of three yearly rounds, roughly half of those positives were cancer, and the test missed most cancers diagnosed during the trial. The paper says the main endpoint, fewer late-stage diagnoses, was not met and is reported elsewhere."@en ;
  schema:url <https://onco.cc/key-papers/paper-nhs-galleri-performance-nat-med-2026/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41591-026-04652-8>, <https://pubmed.ncbi.nlm.nih.gov/42773209/>, <https://clinicaltrials.gov/study/NCT05611632>, <https://www.isrctn.com/ISRCTN91431511> ;
  schema:sameAs <https://doi.org/10.1038/s41591-026-04652-8> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Neal RD, Dolly S, Johnson P, et al." ;
  onco:related <https://onco.cc/key-papers/paper-nhs-galleri-design-cancers-2022/>, <https://onco.cc/key-papers/paper-pathfinder-lancet-2023/>, <https://onco.cc/roadmaps/ctdna-tests/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/anal/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/urothelial/> ;
  onco:sections <https://onco.cc/fronts/early-detection/> ;
  onco:technologies <https://onco.cc/technologies/mced/>, <https://onco.cc/technologies/cfdna-methylation-testing/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:drugs <https://onco.cc/drugs/galleri/> ;
  onco:companies <https://onco.cc/companies/grail/> ;
  onco:terms <https://onco.cc/terms/ppv/>, <https://onco.cc/terms/stage-shift/>, <https://onco.cc/terms/screening/>, <https://onco.cc/terms/sensitivity-specificity/> ;
  onco:trials <https://onco.cc/trials/nhs-galleri/> ;
  onco:people <https://onco.cc/people/peter-sasieni/>, <https://onco.cc/people/charles-swanton/>, <https://onco.cc/people/peter-johnson/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-early-detection/>, <https://onco.cc/bottlenecks/b-overdiagnosis/> ;
  onco:journals <https://onco.cc/journals/nature-medicine/> .